In mid-2019, Novacyt’s stock (AIM: NCYT; Euronext Growth: ALNOV) was trading at a fraction of its future value. Share Price | Novacyt

In early 2019, the company successfully raised approximately €785,000 to fund this expansion, showing strong investor confidence despite its small-cap status at the time.

During this period, Novacyt was transitioning from a niche diagnostics player into a more integrated international group. The company focused on three primary pillars:

That same month, Novacyt’s Lab21 unit launched six new products in its PathFlow™ range, targeting pathogens like C. difficile and Norovirus. 📉 Financial Performance and Stock Context

Novacyt had recently moved to acquire Australian distributor SCD to accelerate its global footprint.